Brief: Arch Biopartners submits orphan drug application for ab569 to European medicines agency
03/02/2016 14:01
Feb 3 (Reuters) - Arch Biopartners Inc ACH.V : * Submits orphan drug application for ab569 to European medicines agency * Says ema is currently reviewing the completeness of the application before initiating the official review process * Source text for Eikon urn:newsml:reuters.com:*:nCCN8hdH2B * Further company coverage ACH.V ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide